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S´ ezary syndrome (SS) is a rare variant of primary cutaneous T-cell lymphoma. Little is known about the underlying pathogenesis
of S. To address this issue, we used Aﬀymetrix 10K SNP microarray to analyse 13 DNA samples isolated from 8 SS patients and
qPCR with ABI TaqMan SNP genotyping assays for the validation of the SNP microarray results. In addition, we tested the impact
of SNP loss of heterozygosity (LOH) identiﬁed in SS cases on the gene expression proﬁles of SS cases detected with Aﬀymetrix
GeneChip U133A. The results showed: (1) frequent SNP copy number change and LOH involving 1, 2p, 3, 4q, 5q, 6, 7p, 8, 9, 10,
11, 12q, 13, 14, 16q, 17, and 20, (2) reduced SNP copy number at FAT gene (4q35) in 75% of SS cases, and (3) the separation of all
SS cases from normal control samples by SNP LOH gene clusters at chromosome regions of 9q31q34, 10p11q26, and 13q11q12.
These ﬁndings provide some intriguing information for our current understanding of the molecular pathogenesis of this tumour
and suggest the possibility of presence of functional SNP LOH in SS tumour cells.
1.Introduction
S´ ezary syndrome (SS) is a rare subset of primary cutaneous
T-cell lymphoma (CTCL) with an aggressive clinical course
[1, 2]. SS typically presents with generalised skin lesions
or erythroderma, intense pruritus, and peripheral lym-
phadenopathy. A blood test will reveal atypical T-lympho-
cytes with convoluted nuclei, S´ ezary cells, which are often
associated with a cutaneous T-cell lymphoma [2–5]. Recent
studies have revealed complex genetic aberrations aﬀecting
almost all chromosomes [6–14]w i t hl o s so fh e t e r o z y g o s i t y
(LOH),[9,15–19]andderegulationofseveralgenes,[20–26]
and epigenetic changes [27, 28] in SS. Despite this progress,
the key molecular targets underlying the pathogenesis of this
type of skin lymphoma remain elusive.
Single nucleotide polymorphism (SNP) denotes a single
base in the DNA sequence that diﬀers from the usual base at
that position. Millions of SNPs have been catalogued in the
humangenome,whichmayberesponsiblefordiseasesuchas
cancer (http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp).
SNP microarray is a powerful genome research technique
designed for the identiﬁcation of SNP and dose change
within the whole genome [29–31]. This method has been
widely used to investigate SNP copy number change and
LOH in cancer genome in a variety of medical and biological
subjects [32–42]. However, there has been no report describ-
ing the use of SNP microarray to assess genomewide SNP
copy number change and LOH in SS in the literature (http://
www.ncbi.nlm.nih.gov/sites/entrez).
ToaddressthisissueweinitiallyperformedSNPmicroar-
ray on DNA samples isolated from biopsies of skin lesions
andperipheralbloodmononuclearcells(PBMCs)ofpatients
with SS by using Aﬀymetrix GeneChip Mapping 10K Xba
assay. Then we assessed gene-speciﬁc SNP copy number
changes in same DNA samples with ABI TaqMan SNP gen-
otyping assays to compare and verify the ﬁndings from Af-
fymetrix10KSNPmicroarrayanalysis.Finally,weconducted
a literature review on LOH ﬁndings of patients with SS. Our
ﬁndings are presented here in this paper.2 Genetics Research International
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Figure 1: Illustration of a diagram of genomewide SNP homozygosity mapping in 8 SS cases (No. 1–8) detected with Aﬀymetrix
GeneChipHumanMapping10KArray(http://www.aﬀymetrix.com/products/arrays/speciﬁc/10k.aﬀx)andanalysedbyusingGOLFsoftware
(https://bioinformatics.cancerresearchuk.org/cazier01). Here each red-coloured line represents copy number gain of individual SNP, green-
coloured line and block stand for SNP copy number loss, black-coloured line and block denote balanced/neutral SNP copy number or
uniparental disomy. Similar SNP homozygosity proﬁle is present in paired DNA samples from the biopsied skin lesion (S) and peripheral
blood (B) isolated from individual patient with SS on the right end of the diagram. Frequent SNP homozygous changes (>3) are seen on
almost all autosomes consistent with SNP copy number alterations shown in Figure 2. The remarkable changes on X chromosome were
used as the internal quality control for the 10K SNP array experiment as green represents X chromosome copy number loss or monosomy
indicating male sex, and black signiﬁes balanced or disomy X chromosome denoting female.
2.MaterialsandMethods
2.1. Sample Selection and DNA Preparation. Eleven patients
with S´ ezary syndrome were selected for this study accord-
ing to the World Health Organization and the European
Organization for Research and Treatment of Cancer diag-
nosis criteria for CTCL [2]. Genomewide SNP analysis
was performed on 8 of these SS cases using Aﬀymetrix
SNP microarray. Five of these 8 SS cases plus additional
3 cases were further assessed with SNP quantitative real-
time PCR in this study. Brieﬂy, a total of 16 DNA samples
(13 samples for SNP microarray and 3 additional samples
for SNP qPCR), which were taken prior to treatment, were
extracted from both PBMCs and biopsied skin lesions from
these SS cases (Figures 1 and 2). This was conducted by
using QIAGEN Genomic-tip 100/G kit (QIAGEN Ltd, West
Sussex, UK) according to the manufacturer’s instruction
(http://www1.qiagen.com/). DNA concentrations and purity
were determined with the NanoDrop ND-1000 spectropho-
tometer (NanoDrop, Rockland, Del, USA). Local ethical
approval for the sampling procedures was obtained previ-
ously [9–11, 18] and the use of the stored DNA samples for
this study was approved by the Research Ethical Committee
atBartsandRoyalLondonSchoolofMedicineandDentistry,
Queen Mary University of London.
2.2. Single Nucleotide Polymorphism Microarray Assay. Af-
fymetrix SNP microarray analysis of 13 DNA samples in-
cluding 5 paired PBMCs and skin biopsies from 8SS pa-
tients (Figure 1) was conducted according to the standard
GeneChip Mapping 10K (V2.0) Xba Assay protocol (Af-
fymetrix Inc., Santa Clara, Calif, USA). Brieﬂy, 350ng of
DNAwasdigestedwithXbaIandligationtotheXbaIadaptor
prior to PCR ampliﬁcation (35 cycles) using AmpliTaq Gold
with Buﬀer II (Applied Biosystems, Foster City, Calif, USA).
HybridisedarrayswereprocessedwithanAﬀymetrixFluidics
Station 450 and ﬂuorescence signals were detected using
the Aﬀymetrix GeneChip Scanner 3000. Signal intensity
data was assessed with the GeneChip DNA analysis soft-
ware (http://www.aﬀymetrix.com/products/arrays/speciﬁc/
10k.aﬀx) based on a model algorithm to generate SNP calls
[43] and subsequent bioinformative analysis was carried out
using an in-house software called GOLF (http://www.bi-
oinformatics.cancerresearchuk.org/cazier01) developed by
Professor Young [44] and a publicly accessible software
named IdeogramBrowser Software (http://www.informatik
.uni-ulm.de/ni/staﬀ/HKestler/ideo/doc.html).
2.3. SNP Quantitative Real-Time PCR Assay. To verify the
results of Aﬀymetrix SNP microarray analysis of SS cases in
this study, SNP qPCR assay was performed to test 10 DNA
samples from 8SS patients including 7 samples from 5SS
cases used in above SNP microarray and 3 samples from
additional 3SS cases (Figure 3). This experiment was carried
out by means of an ABI Prism 7900 sequence detectionGenetics Research International 3
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Figure 2: Illustration of an ideogram of genomewide SNP copy number changes in 8SS cases identiﬁed by using Aﬀymetrix
GeneChip Human Mapping 10K Array as above and analysed with the IdeogramBrowser Software (http://www.informatik.uni-
ulm.de/ni/staﬀ/HKestler/ideo/doc.html). Here each red-coloured dot represents copy number loss of individual SNP and green-coloured
dot stands for SNP copy number gain. Frequent SNP copy number changes at chromosomes 1, 2p, 3, 4q, 5q, 6, 7p, 8, 9, 10, 11, 12q, 13, 14,
16q, 17, and 20 are clearly visible.
Gene SNP TaqMan SNP genotyping assay ID Location SS1a SS1b SS3 SS5a SS5b SS6 SS8 SS9 SS10 SS11
RAB1A rs10519011 C 30505234 20 2p14
STAT4 rs13001658 2q32.2q32.3
VEGFC rs1485765 4q34.1q34.3
FAT rs1280100 4q35
TWIST1 rs2106892 7p21.2
BNIP3L rs1042992 8p21
NFIB rs2078463 9p24.1
AKR1C3 rs7068685 10p15p14
TAGLN rs2269397 C 26872972 10 11q23.2
NFIB rs2382446 chr12
TRIM16 rs9909923 17p11.2
PLS3 rs5987755 Xq23
C 26419547 10
C 8850347 20
C 11250338 10
C 26517452 10
C 8796859 20
C 16110577 10
C 11654325 20
C 27086526 10
C 30222562 10
C 30587612 20
Figure 3: A summary of SNP copy number changes of 12 genes in 10SS samples by using qPCR with ABI TaqMan SNP genotyping assay
to verify the results of Aﬀymetrix 10K SNP microarray analysis of SS in this study. Here red-coloured rectangular bar denotes SNP copy
number loss against internal controls of B2M and GAPDH, green-coloured bar stands for SNP copy number gain, yellow-coloured bar
represents balanced/neutral or normal SNP copy number, and gray-coloured bar indicates noninformative. Frequent SNP copy number
losses of VEGFC, FAT, NFIB, and TRIM16 are clearly visible.4 Genetics Research International
systemusingtheTaqManPCRMasterMixwithTaqManSNP
genotyping assays (http://www3.appliedbiosystems.com/ap-
plicationstechnolo-gies/real-timepcr/index.htm). These as-
says amplify 12 genes within the chromosomal regions
showing frequent SNP copy number changes identiﬁed in
this study (Figure 2). Additional 2 SNP genotyping assays
amplifying beta-2-microglobulin (B2M, rs935885, C
12080829 10) and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH, rs3741918, C 27510362 10) were used as
the internal quality controls. qPCR reactions contained
900nmol primers, 200nmol probes, 400mM each dATP,
dCTP and dGTP, 800mM dUTP, 1U Amplitaq Gold DNA
polymerase, 0.2U AmpErase uracil N-glycosylase (UNG),
and 13 TaqMan buﬀer in a total volume of 25μL in 96-well
microtiter plate (Applied Biosystems). After a decontam-
ination step at 50◦C, a two-step protocol was followed for
50 cycles: 95◦C for 15s and 61◦C for 1min. SNP qPCR
data analysis was conducted as previously described [45]
with ABI SNPbrowser Software (http://marketing.applied-
biosystems.com/mk/get/snpb landing).
2.4. SNP Loss of Heterozygosity Expression Proﬁling. We have
previously put forward a concept of functional copy number
changes in cancer cells [46]. To further test our hypothesis
in this study, we assume a SNP LOH gene cluster in SS is
bioinformatically signiﬁcant or functional if it is capable of
separating all SS cases from normal control (NC) samples.
This test was carried out through a data mining experiment
by using a bioinformative method developed by us [46].
In this experiment, the eﬀect of SNP LOH detected in this
study on gene expression proﬁling in SS cases conducted in
previous studies [23, 24, 47] was tested as before [46]. The
procedures were brieﬂy described as follows. We initially
created gene lists from 9 chromosomal regions showing
frequent LOH (>3 per region) at SNP level seen in SS
(Table 1) by using IdeogramBrowser Software and UCSC
Human Gene Sorter (http://www.genome.ucsc.edu/). Then
we imported these 9 gene-lists into GeneSpring software
version 7 (http://www.sigenetics.com/), which contained
a genome/raw data of gene expression proﬁle from 6 SS
patients who were treated with photopheresis therapy and 2
healthy individuals generated by using Aﬀymetrix GeneChip
U133A (http://www.aﬀymetrix.com/products/arrays/spe-
ciﬁc/hgu133av2.aﬀx). Of 6 SS cases analysed with Aﬀymetrix
gene expression microarray the 3 cases were also tested by
above Aﬀymetrix SNP microarray. Finally, we analysed the
selected 9 gene lists by using the clustering tool of Gene-
Spring to generate gene tree and condition tree, a supervised
clustering, which enables direct visualisation of sample
congregation and separation [46].
2.5.ComparisonwithPublishedDataonLOHatMicrosatellite
Loci in SS. The genomic region where SNPs span on
Aﬀymetrix 10K GeneChip used in this study is equivalent to
that covered by 400 microsatellite (MS) loci (http://www.af-
fymetrix.com/products/arrays/speciﬁc/10k.aﬀx). There have
been several publications describing LOH at MS loci on
limited chromosomes in CTCL including SS [9, 15–19, 48].
Table 1: A summary of gene expression proﬁle of LOH gene
clusters.
Chromosomal regions
with LOH detected in
this study
Number of genes Separation of SS
from NC∗
1p36p33 80 N
2q21q24 9 N
8q22q24 15 N
9q31q34 40 P
10p11q26 111 P
11q21q25 205 N
13q11q12 15 P
16q21q23 74 N
17p13q11 198 N
∗N: no separation between SS and NC, P: presence of separation between SS
and NC.
To compare previous ﬁndings with this study, we reanalysed
previous published data on MS LOH at chromosomes 1
and 10q through ﬁne mapping of each MS locus, which
was linked to individual gene and SNP by using NCBI
ENTREZ GENE and ENTREZ SNP database (http://www
.ncbi.nlm.nih.gov/).
3. Results
3.1.SNPMicroarray. Inthisstudy,pairedDNAsamplesfrom
PBMCs and skin lesions from 5 of 8SS cases were analysed
with Aﬀymetrix 10K SNP microarray, which showed similar
SNP homozygous changes between the paired samples
indicating they are coming from the same individual. There
was a diﬀerence in SNP ﬁngerprint among 8 diﬀerent SS
cases signifying the absence of sample contamination. As
Figure 1 shows, frequent homozygous changes (>3p e rc h r o -
mosome) including gain, loss, and uniparental disomy
(UPD) were seen to distribute throughout almost an entire
genome except of chromosomes 14, 19 and 22.
As Figure 2 shows there were frequent SNP copy number
changes (>3 per chromosome) at chromosomes 1, 2p, 3, 4q,
5q, 6, 7p, 8, 9, 10, 11, 12q, 13, 14, 16q, 17, and 20, which are
not only consistent with above homozygous changes but also
in line with previous CGH ﬁndings in SS [10].
In this study, a weak and/or smear band of TCR gene was
detected in skin DNA samples, while a strong monoclonal
TCR gene band was seen in PBMC DNA samples (data not
shown), suggesting that only a few tumour cells were
present in skin samples and sample contamination was neg-
ligible. Overall, a frequent LOH was noted in 5 paired
SS cases at 9 chromosomal regions including 1p36p33,
2q21q24, 8q22q24, 9q31q34, 10p11q26, 11q21q25,
13q11q12, 16q21q23, and 17p13q11 (Table 1), which are to
some extent similar to previous reports on LOH at certain
chromosome regions [9, 15–19].
3.2. SNP qPCR Assay. To further conﬁrm SNP microarray
ﬁndings, SNP qPCR was utilised to test DNA samples from 5
of 8 SS cases (case number 1, 3, 5, 6 and 8) analysed withGenetics Research International 5
Aﬀymetrix 10K SNP microarray using ABI TaqMan SNP
genotyping assay (63%) and 3 additional cases. As Figure 3
shows, frequent SNP copy number loss (>2 cases) at the FAT
gene (rs1280100) at 4q35 was observed in 6 of 8 SS cases
( n u m b e r1 ,3 ,6 ,8 ,9 ,a n d1 0 )( 7 5 % ) ,f o l l o w e db yV E G F C
(rs1485765) at 4q34.1q34.3 (cases 3, 6, 8, and 9) (50%),
NFIB (rs2382446) at chromosome 12 (cases 5, 6 and 8)
(38%), and TRIM16 (rs9909923) at 17p11.2 (cases 3, 6,
and 8) (38%). While frequent SNP copy number gain (>2
cases) was also noted at the AKR1C3 gene (rs7068685, 50%),
VEGFC (rs1485765, 38%), and TAGLN (rs2269397, 38%).
SNP copy number changes were most frequent present
in SS case 3, which showed losses of genes of RAB1A
(rs10519011, 2p14), VEGFC, FAT, AKR1C3, TRIM16,
and PLS3 (rs5987755, Xq23) as well as gains of genes of
TAGLN (rs2269397, 11q23.2) and NFIB. This was followed
by case 5, which had gains of RAB1A, STAT4 (rs13001658,
2q32.2q32.3), VEGFC, TWIST1 (rs2106892, 7p21.2),
TAGLN, and PLS3, and loss of NFIB. Case 6 revealed losses
of VEGFC, FAT, NFIB and TRIM16, and gain of AKR1C3;
case 8 demonstrated losses of VEGFC, FAT, AKR1C3, NFIB,
and TRIM16 (Figure 3). Overall these SNP copy number
changes, detected by using qPCR with ABI TaqMan SNP
genotyping assay, were consistent with those identiﬁed by
using Aﬀymetrix 10K SNP microarray as shown in Figure 2.
3.3. SNP LOH Expression Proﬁling. The impact of SNP LOH
gene cluster on gene expression pattern was further tested
in this study. As shown in Figure 4, the clusters of 2 NCs
appeared at the right end of the heatmap and the clusters of
6SScaseswerepresentinthemiddleandattheleftendofthe
heatmap.Thisclearlyshowedthattwogroupswereseparated
and diﬀerent. Over the 9 SNP LOH gene lists analysed in
this study, 3 (33%) showed gene expression patterns of the
separation of 6SS cases from 2 NCs (Table 1). This included
SNP LOH gene clusters at 9q31q34 (40 genes), 10p11q26
(111 genes), and 13q11q12 (15 genes) (Figure 4). Each
individual gene in these 3 gene clusters is listed in Table 2.
However, the remaining 6 SNP LOH gene lists revealed a
mixed gene expression pattern without the separation of SS
from NCs (Table 1).
3.4. Reﬁning Previous SS LOH Data and Comparing with
This Study. Previous studies have shown LOH on several
chromosomes including chromosomes 1 and 10q [9, 15–
19, 48]. The 10K SNP microarray gene chip used in this
studyisequivalenttothegeneticdistancecoveredby400MS.
This allows us to compare SNP LOH identiﬁed in this study
with MS LOH described in those previous studies. Frequent
LOH at MS loci D1S247 (rs11372930) at 1p36 and D10S562
(rs4128597) at 10q25.3 (Figure 5)r e p o r t e di np r e v i o u s
studies [9, 18, 19] were seen in this study.
4. Discussion
This integrated genomic study has for the ﬁrst time revealed
genomewide SNP copy number change and LOH as well as
SNP LOH gene expression proﬁling in SS cases. Although
the number of SS cases tested in this study was small, the
patterns of SNP copy number change and LOH identiﬁed
in SS cases are generally in line with previous metaphase-
/array-CGH [6–14] and MS LOH studies [9, 15, 17–19, 48],
suggesting the high eﬃciency and reliability of the methods
used.Inadditionsomenovelﬁndingsemerged.Thisincludes
the presence of SNP copy number loss at the FAT gene
(4q35) in most SS cases and the separation of all SS cases
from NC samples by SNP LOH gene clusters at chromosome
regions of 9q31q34, 10p11q26, and 13q11q12. Although all
of these results will need to be validated in larger cohorts
of samples from SS patients in the future, they do provide
some intriguing information for our current understanding
of the molecular pathogenesis of this type of lymphoma and
suggest the possibility of presence of functional SNP LOH in
SS tumour cells at least from the point of view of bioinfor-
matics.
S´ ezary syndrome is a rare form of CTCL with an aggres-
sive clinical course and it also likely represents the leukaemic
phase of mycosis fungoides [1, 2]. Like any other advanced
stageofmalignancies,SSaccumulatesavarietyofgeneticand
epigenetic events including alterations of tumour suppressor
genes,oncogenes,andsomekeyhouse-keepinggenes[18,27,
28, 49]. Previous studies on SS have shown complex genetic
aberrations aﬀecting almost all chromosomes with copy
number losses being the dominant abnormalities, which
mainly involve chromosomes 1p, 6q, 9, 10, 13q, and 17p
[6–14] and the presence of LOH at MS loci on chromosomes
1p, 9p, 10q, and 17p in tumour cells [9, 15–19, 48]. In
addition, downregulation of several genes including MXI1
(10q24q25) and upregulation of genes such as TWIST1
(7p21.2) and PLS3 (Xq23) have also been described in this
malignancy [20–26]. Similar results were obtained in this
study, which showed SNP copy number change on chromo-
somes 1, 2p, 3, 4q, 5q, 6, 7p, 8, 9, 10, 11, 12q, 13, 14, 16q, 17,
and 20, and LOH at 1p, 2q, 8q, 9q, 10, 11q, 13q, 16q, and 17
as well as SNP copy number gains of TWIST1 and PLS3 in 2
SS cases, further indicating the high eﬃciency and reliability
of the integrated genomic experiments conducted in this
study.
Although there are diﬀerent deﬁnitions for loss of het-
erozygosity in literature, LOH is generally deﬁned as a locus
or loci at which a deletion or other process has converted the
locus from heterozygosity to homozygosity or hemizygosity.
In terms of cancer, LOH signiﬁes that in tumour cells
carrying a mutated allele of a tumour suppressor gene,
the gene becomes fully inactivated when the cell loses a
large part of the chromosome carrying the wild-type allele
(http://www.ncbi.nlm.nih.gov/cancerchromosomes).LOHis
traditionally used as a molecular tool to identify a tumour-
suppressor gene but it also represents one of the most com-
mon molecular features of cancer cells [47, 50–52]. Previous
studies have shown LOH at MS loci on chromosomes 1p,
9p, 10q, 12q, 13q, 17p, and 19 in CTCL including SS [9, 15–
19, 48]. This was supported by previous conventional cyto-
geneticsand metaphaseandarray-basedCGH studies,which
revealed DNA copy number losses at these chromosomal
regions [6–14, 48]. In this study LOH at SNP level on 9 chro-
mosomal regions (1p, 2q, 8q, 9q, 10, 11q, 13q, 16q, and 17)6 Genetics Research International
36830 at(MIPEP)
208740 at(SAP18)
208742 at(SAP18) s
218479 at(XPO4) s
204386 s at(MRP63)
204305 at(MIPEP)
213262 at(SACS)
s 221995 at(MRP63)
208741 at(SAP18)
s 221771 at(HSMPP8)
s 220753 at(CRYL1)
206404 at(FGF9)
207302 at(SGCG)
SS SS SS SS SS SS NC NC
1
·
·
·
204387 at(MRP63) x
208590 at(GJA3) x
15 s from 13q loh gene list SSvcontrol (8samples) gene
Figure 4: Illustration of a heatmap of gene expression proﬁle of SNP LOH at 13q11q12 gene cluster (15 genes). Here each column represents
one test sample and each coloured rectangular bar signiﬁes each individual gene. The colouration of each bar indicates the expression level
of individual gene, which has been reported previously [23, 24, 47] and is not the focus of this study. The separation of 6 S´ ezary syndrome
cases (SS, left and middle) from 2 normal controls (NC, right) is clearly visible and two test groups are diﬀerent.
MS Loci Gene SNP Location SS20 MF15 SS24 SS22 MF12 MF8 MF7 MF6 MF13
D10S583 CDC2 rs57066318 10q21.1
D10S581 EGR2 rs61865883 10q21.1
D10S541 BMPR1A rs6586038 10q22.3
D10S192 HPS1 rs59684510 10q23.1q23.3
D10S215 PAPSS2 rs4934358 10q23q24
D10S571 SORBS1 rs4146488 10q23.3q24.1
D10S185 FER1L3 rs871422 10q24
D10S198 PAX2 rs11819541 10q24
D10S603 PKD2L1 rs3853518 10q24
D10S190 CYP17A1 rs45504696 10q24.3
D10S222 NEURL rs11191726 10q25.1
D10S562 TCF7L2 rs4128597 10q25.3
D10S187 KIAA1598 rs7099910 10q25.3
D10S530 DMBT1 rs1960177 10q25.3q26.1
D10S221 PDZD8 rs2532837 10q25.3q26.11
D10S587 FGFR2 rs2981582 10q26
D10S544 HSPA12A rs2907230 10q26.12
D10S209 PPAPDC1A rs4752440 10q26.12
SS26 SS16 SS19 SS23 SS25 MF10 MF4 MF14 SS18 SS21 SS17 MF1 MF5 MF9 MF11 MF3 MF2
Figure 5: A summary of reanalysis of previously published LOH at 18 microsatellite loci on 10q21q26 in SS and MF [19] with this study, in
which each microsatellite locus is ﬁnely mapped and linked to individual gene and SNP via NCBI ENTREZ GENE and ENTREZ SNP
database (http://www.ncbi.nlm.nih.gov/). Here black bar represents LOH, gray bar stands for noninformative, and white bar indicates
microsatellite marker that is not available. One SNP within microsatellite locus D10S562 (bold) is also present in the SNP LOH cluster
at 10p11q26 in this study (Table 1).Genetics Research International 7
Table 2: A detailed gene list of the 3 LOH gene clusters separating SS from NC
LOH gene clusters Gene name Common Description
9q31q34 221294 at GPR21 G-protein-coupled receptor 21
221085 at TNFSF15 Tumor necrosis factor (ligand) superfamily, member 15
220935 s at CDK5RAP2 CDK5 regulatory subunit associated protein 2
220300 at RGS3 Regulator of G-protein signalling 3
220202 s at MNAB Membrane-associated nucleic acid binding protein
220201 at MNAB Membrane-associated nucleic acid binding protein
219884 at LHX6 LIM homeobox protein 6
218941 at FBXW2 F-box and WD-40 domain protein 2
218489 s at ALAD Aminolevulinate, delta-, dehydratase
218487 at ALAD Aminolevulinate, delta-, dehydratase
218160 at NDUFA8 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8, 19kDa
215813 s at PTGS1 Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and
cyclooxygenase)
214465 at ORM2 Orosomucoid 2
214425 at AMBP Alpha-1-microglobulin/bikunin precursor
214040 s at GSN Gelsolin (amyloidosis, Finnish type)
211503 s at RAB14 RAB14, member RAS oncogene family
210825 s at STOM Stomatin
210824 at STOM Stomatin
209162 s at PRPF4 PRP4 pre-mRNA processing factor 4 homolog (yeast)
209161 at PRPF4 PRP4 pre-mRNA processing factor 4 homolog (yeast)
208828 at POLE3 Polymerase (DNA directed), epsilon 3 (p17 subunit)
208737 at ATP6V1G1 ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G isoform 1
205599 at TRAF1 TNF receptor-associated factor 1
205500 at C5 Complement component 5
205477 s at AMBP Alpha-1-microglobulin/bikunin precursor
205128 x at PTGS1 Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and
cyclooxygenase)
205127 at PTGS1 Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and
cyclooxygenase)
205041 s at ORM1 Orosomucoid 1
205040 at ORM1 Orosomucoid 1
204449 at PDCL Phosducin-like
204448 s at PDCL Phosducin-like
203971 at SLC31A1 Solute carrier family 31 (copper transporters), member 1
203823 at RGS3 Regulator of G-protein signalling 3
203447 at PSMD5 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 5
201062 at STOM Stomatin
201061 s at STOM Stomatin
201060 x at STOM Stomatin
200928 s at RAB14 RAB14, member RAS oncogene family
200927 s at RAB14 RAB14, member RAS oncogene family
200696 s at GSN Gelsolin (amyloidosis, Finnish type)
10p11.21q26.3 32094 at CHST3 Carbohydrate (chondroitin 6) sulfotransferase 3
222072 at ADD3 Homo sapiens clone DT1P1A11 mRNA, CAG repeat region
221136 at GDF2 Growth diﬀerentiation factor 2
219963 at DUSP13 Dual speciﬁcity phosphatase 13
219957 at RUFY2 RUN and FYVE domain containing 2
219543 at MAWBP MAWD binding protein
219509 at MYOZ1 Myozenin 18 Genetics Research International
Table 2: Continued.
LOH gene clusters Gene name Common Description
218878 s at SIRT1 Sirtuin (silent mating type information regulation 2 homolog) 1 (S.
cerevisiae)
218871 x at GALNACT-2 Chondroitin sulfate GalNAcT-2
218445 at H2AFY2 H2A histone family, member Y2
218249 at ZDHHC6 Zinc ﬁnger, DHHC domain containing 6
218046 s at MRPS16 Mitochondrial ribosomal protein S16
218006 s at ZNF22 Zinc ﬁnger protein 22 (KOX 15)
218005 at ZNF22 Zinc ﬁnger protein 22 (KOX 15)
216903 s at CBARA1 Calcium binding atopy-related autoantigen 1
216345 at KIAA0913 KIAA0913 protein
216037 x at TCF7L2 Transcription factor 7-like 2 (T-cell speciﬁc, HMG-box)
216035 x at TCF7L2 Transcription factor 7-like 2 (T-cell speciﬁc, HMG-box)
214878 at ZNF37A Zinc ﬁnger protein 37a (KOX 21)
214617 at PRF1 Perforin 1 (pore forming protein)
214508 x at CREM cAMP responsive element modulator
214366 s at ALOX5 Arachidonate 5-lipoxygenase
214348 at TACR2 Tachykinin receptor 2
214338 at DNAJB12 DnaJ (Hsp40) homolog, subfamily B, member 12
214322 at CAMK2G Calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma
214136 at NUDT13 Nudix (nucleoside diphosphate linked moiety X)-type motif 13
213952 s at ALOX5 Arachidonate 5-lipoxygenase
213647 at DNA2L DNA2 DNA replication helicase 2-like (yeast)
212894 at SUPV3L1 Suppressor of var1, 3-like 1 (S. cerevisiae)
212762 s at TCF7L2 Transcription factor 7-like 2 (T-cell speciﬁc, HMG-box)
212761 at TCF7L2 Transcription factor 7-like 2 (T-cell speciﬁc, HMG-box)
212759 s at TCF7L2 Transcription factor 7-like 2 (T-cell speciﬁc, HMG-box)
212757 s at CAMK2G Calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma
212669 at CAMK2G Calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma
212594 at PDCD4 Programmed cell death 4 (neoplastic transformation inhibitor)
212593 s at PDCD4 Programmed cell death 4 (neoplastic transformation inhibitor)
212359 s at KIAA0913 KIAA0913 protein
212322 at SGPL1 Sphingosine-1-phosphate lyase 1
212321 at SGPL1 Sphingosine-1-phosphate lyase 1
211809 x at COL13A1 Collagen, type XIII, alpha 1
211668 s at PLAU plasminogen activator, urokinase
211343 s at COL13A1 Collagen, type XIII, alpha 1
210956 at PPYR1 Pancreatic polypeptide receptor 1
210671 x at MAPK8 Mitogen-activated protein kinase 8
210588 x at HNRPH3 Heterogeneous nuclear ribonucleoprotein H3 (2H9)
210477 x at MAPK8 Mitogen-activated protein kinase 8
210318 at RBP3 Retinol binding protein 3, interstitial
210171 s at CREM cAMP responsive element modulator
210110 x at HNRPH3 Heterogeneous nuclear ribonucleoprotein H3 (2H9)
209910 at SLC25A16 Solute carrier family 25 (mitochondrial carrier; Graves disease
autoantigen), member 16
209869 at ADRA2A Adrenergic, alpha-2A-, receptor
209860 s at ANXA7 Annexin A7
209834 at CHST3 Carbohydrate (chondroitin 6) sulfotransferase 3
209817 at PPP3CB Protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform
(calcineurin A beta)Genetics Research International 9
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209538 at ZNF32 Zinc ﬁnger protein 32 (KOX 30)
209457 at DUSP5 Dual speciﬁcity phosphatase 5
209045 at XPNPEP1 X-prolyl aminopeptidase (aminopeptidase P) 1, soluble
208990 s at HNRPH3 Heterogeneous nuclear ribonucleoprotein H3 (2H9)
208770 s at EIF4EBP2 Eukaryotic translation initiation factor 4E binding protein 2
208769 at EIF4EBP2 Eukaryotic translation initiation factor 4E binding protein 2
208535 x at COL13A1 Collagen, type XIII, alpha 1
208453 s at XPNPEP1 X-prolyl aminopeptidase (aminopeptidase P) 1, soluble
208381 s at SGPL1 Sphingosine-1-phosphate lyase 1
208252 s at CHST3 Carbohydrate (chondroitin 6) sulfotransferase 3
208152 s at DDX21 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 21
208095 s at CAMK2G Calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma
207965 at NEUROG3 Neurogenin 3
207630 s at CREM cAMP responsive element modulator
207543 s at P4HA1 Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline
4-hydroxylase), alpha polypeptide I
207347 at ERCC6 Excision repair cross-complementing rodent repair deﬁciency,
complementation group 6
207127 s at HNRPH3 Heterogeneous nuclear ribonucleoprotein H3 (2H9)
206747 at KIAA0514 KIAA0514 gene product
206261 at ZNF239 Zinc ﬁnger protein 239
206159 at GDF10 Growth diﬀerentiation factor 10
206010 at HABP2 Hyaluronan binding protein 2
205882 x at ADD3 Adducin 3 (gamma)
205879 x at RET Ret proto-oncogene (multiple endocrine neoplasia and medullary thyroid
carcinoma 1, Hirschsprung disease)
205479 s at PLAU Plasminogen activator, urokinase
204446 s at ALOX5 Arachidonate 5-lipoxygenase
204445 s at ALOX5 Arachidonate 5-lipoxygenase
204120 s at ADK Adenosine kinase
204119 s at ADK Adenosine kinase
203916 at NDST2 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 2
203666 at CXCL12 Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1)
203187 at DOCK1 Dedicator of cyto-kinesis 1
203079 s at CUL2 Cullin 2
203078 at CUL2 Cullin 2
203074 at ANXA8 Annexin A8
202867 s at DNAJB12 DnaJ (Hsp40) homolog, subfamily B, member 12
202866 at DNAJB12 DnaJ (Hsp40) homolog, subfamily B, member 12
202865 at DNAJB12 DnaJ (Hsp40) homolog, subfamily B, member 12
202777 at SHOC2 soc-2 suppressor of clear homolog (C. elegans)
202731 at PDCD4 Programmed cell death 4 (neoplastic transformation inhibitor)
202730 s at PDCD4 Programmed cell death 4 (neoplastic transformation inhibitor)
202524 s at SPOCK2 Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2
202523 s at SPOCK2 Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2
202432 at PPP3CB Protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform
(calcineurin A beta)
202364 at MXI1 MAX interacting protein 1
202361 at SEC24C SEC24 related gene family, member C (S. cerevisiae)
201859 at PRG1 Proteoglycan 1, secretory granule10 Genetics Research International
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201858 s at PRG1 Proteoglycan 1, secretory granule
201753 s at ADD3 Adducin 3 (gamma)
201752 s at ADD3 Adducin 3 (gamma)
201376 s at HNRPF Heterogeneous nuclear ribonucleoprotein F
201366 at ANXA7 Annexin A7
201034 at ADD3 Adducin 3 (gamma)
200931 s at VCL Vinculin
200930 s at VCL Vinculin
200871 s at PSAP Prosaposin (variant Gaucher disease and variant metachromatic
leukodystrophy)
200866 s at PSAP Prosaposin (variant Gaucher disease and variant metachromatic
leukodystrophy)
200697 at HK1 Hexokinase 1
13q11q12 36830 at MIPEP Mitochondrial intermediate peptidase
221995 s at MRP63 Mitochondrial ribosomal protein 63
221771 s at HSMPP8 M-phase phosphoprotein, mpp8
220753 s at CRYL1 Crystallin, lambda 1
218479 s at XPO4 Exportin 4
213262 at SACS Spastic ataxia of Charlevoix-Saguenay (sacsin)
208742 s at SAP18 sin3-associated polypeptide, 18kDa
208741 at SAP18 sin3-associated polypeptide, 18kDa
208740 at SAP18 sin3-associated polypeptide, 18kDa
208590 x at GJA3 Gap junction protein, alpha 3, 46kDa (connexin 46)
207302 at SGCG Sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein)
206404 at FGF9 Fibroblast growth factor 9 (glia-activating factor)
204387 x at MRP63 Mitochondrial ribosomal protein 63
204386 s at MRP63 Mitochondrial ribosomal protein 63
204305 at MIPEP Mitochondrial intermediate peptidase
was identiﬁed in SS cases by using Aﬀymetrix 10K Gene-
Chip, which covers approximately 400 MS loci. There was
an overlap between this and previous studies on LOH at
chromosome 1p (D1S247) and 10q (D10S562). Previous
studies also suggested LOH at 1p and 10q associated with
late stage CTCL [15–17, 19, 48]. In addition, copy number
losses were described in these 9 chromosomal regions by
using molecular cytogenetic techniques as discussed above.
Furthermore, these ﬁndings were subsequently validated by
extensive SNP qPCR test in this study. Taking together all
of these results suggest that some of these SNP LOH and
copy number changes are likely to be associated with the
pathogenesis of SS.
The FAT gene, which is expressed at high levels in a
number of foetal epithelia, is an ortholog of the Drosophila
fat gene. FAT encodes a tumour suppressor essential for
controlling cell proliferation during Drosophila develop-
ment. Its product is a member of the cadherin superfamily,
a group of integral membrane proteins characterised by
the presence of 34 tandem cadherin-type repeats as well as
ﬁve epidermal growth factor-like repeats and one laminin
A-G domain with possible functions as an adhesion
molecule and/or signalling receptor, which are likely to be
associated with developmental processes and cell communi-
cation (http://www.ncbi.nlm.nih.gov/gene/2195). The FAT
gene is located on human chromosome 4q35. Previous
molecular cytogenetic studies have revealed copy num-
ber losses at this chromosomal region in a variety of
cancers (http://www.progenetix.org/cgi-bin/pgCasesMatrix-
Plotter.cgi). Furthermore deletion/LOH and absent expres-
sion of FAT have also been found in oral cancer [53]a n d
human astrocytic tumours [54]. Intriguingly, in this study
SNP copy number loss of FAT was observed in three-quarter
of SS cases and reduced gene expression of FAT was also
noted in most cutaneous squamous cell carcinoma cases
(data not shown) no spare SS RNA samples are available
for qPCR testing. These results further indicate the tumour
suppressor role of FAT and also suggest that loss of FAT is
relevant to SS pathology.
Interindividual copy number variation/polymorphism
(CNV/P)isthoughttobethemanifestationofaconsiderable
and unanticipated plasticity of the human genome. CNV/P
constitutes a major source of interindividual genetic
variation that could explain variable penetrance of inherited
diseases and variation in the phenotypic expression of
aneuploidies and sporadic traits [55, 56]. There is increasingGenetics Research International 11
evidence showing de novo CNV/P as a major cause of
mental retardation and several other complex disorders [38–
40, 43, 57]. Cytogenetically CNV/P or copy number changes
(CNCs) have long been described in cancer cells (http://
www.cgap.nci.nih.gov/Chromosomes/Mitelman,http://www
.progenetix.net/). As discussed above SS has been found
with frequent CNCs at several chromosomal regions [6–13].
SomeoftheseCNCsmayhaveaneteﬀectongeneexpression
as previous expression proﬁling studies on SS have revealed
up- and downregulations ofseveral genes,whichare mapped
within the chromosomal regions harbouring these CNCs
[20–26]. From, bioinformatic point of view these CNCs may
be functional. Whilst the remaining CNCs (CNV/P) may
not have any net eﬀect at all and are therefore nonfunctional.
To test this hypothesis we developed a simple bioinformatics
strategy through the analysis of the expression proﬁling
of CNCs gene clusters commonly presented in SS to see if
SS cases can be separated from NCs. We found separated
expression patterns in 4 of 17 CNCs gene clusters [46]. In
this study, we expanded the scope of our bioinformatics
experiment by examining the impact of common SNP LOH
gene clusters identiﬁed in SS cases with Aﬀymetrix 10K SNP
microarray on gene expression patterns in SS cases detected
using gene expression microarray with Aﬀymetrix GeneChip
U133A and dedicated software. There was a separation
o fa l l6 S Sc a s e sf r o m2N C sb y3o f9S N PL O Hg e n e
clusters. This includes 9q31q34, 10p11q26, and 13q11q12,
which lie within the chromosomal regions showing frequent
LOH and/or DNA copy number loss in SS. In addition,
decreased expression of MXI1 in SNP LOH gene cluster at
10p11q26 has been described in SS previously [22]. All of
these ﬁndings suggest that the 3 SNP LOH gene clusters may
be functional in terms of bioinformatics and relevant to SS
pathology. There are also a number of genes in these 3 SNP
LOH gene lists which have not been described in SS before.
Further functional studies, including proteomic analysis, are
therefore necessary to elucidate the oncogenic role of these
genes in the initiation and progression of SS and other types
of CTCL.
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